Antibiotic hybrids: The next generation of agents and adjuvants against gram-negative pathogens?

Clinical Microbiology Reviews

Volumn 31, Issue 2, 2018, Pages

  Domalaon, Ronald ^a   Idowu, Temilolu ^a   Zhanel, George G ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibacterial; Antibiotic; Antimicrobial; Efflux; Hybrid; Permeability

Indexed keywords

ADJUVANT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASPERGILLOMARASMINE A; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFIDEROCOL; CEFTAROLINE FOSAMIL; CEFTOLOZANE PLUS TAZOBACTAM; CILASTATIN; CIPROFLOXACIN; DALBAVANCIN; DELAFLOXACIN; FIDAXOMICIN; FINAFLOXACIN; FRAMYCETIN; IMIPENEM; MEROPENEM PLUS VABORBACTAM; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; POLYAMINOACID; RELEBACTAM; RIFAMPICIN; SECNIDAZOLE; TEDIZOLID; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; DRUG PENETRATION; EFFUSION; GRAM NEGATIVE BACTERIUM; HUMAN; MEMBRANE TRANSPORT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRULENCE; DRUG DEVELOPMENT; DRUG EFFECT; GRAM NEGATIVE INFECTION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG DEVELOPMENT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS;

EID: 85044227303     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00077-17     Document Type: Review

References (330)

1. Lowy, F. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111:1265–1273. https://doi.org/10.1172/JCI18535.
2. Yoneyama, H, Katsumata R. 2006. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci Biotechnol Biochem 70:1060–1075. https://doi.org/10.1271/bbb.70.1060.
3. Boucher, HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. https://doi.org/10.1086/595011.
4. Rice, LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079–1081. https://doi.org/10.1086/533452.
5. Rice, LB. 2010. Progress and challenges in implementing the research on ESKAPE pathogens. Infect Control Hosp Epidemiol 31:S7–S10. https://doi.org/10.1086/655995.
6. Karlowsky, JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. 2017. Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015. Braz, J Infect Dis 21:343–348. https://doi.org/10.1016/j.bjid.2017.03.006.
7. Karlowsky, JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF. 2017. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. J Med Microbiol 66:61–69. https://doi.org/10.1099/jmm.0.000421.
8. Cardoso, T, Ribeiro O, Aragao IC, Costa-Pereira A, Sarmento AE. 2012. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis 12:375. https://doi.org/10.1186/1471-2334-12-375.
9. Magiorakos, A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
10. Ho, J, Tambyah PA, Paterson DL. 2010. Multiresistant, Gram-negative infections: a global perspective. Curr Opin Infect Dis 23:546–553. https://doi.org/10.1097/QCO.0b013e32833f0d3e.
11. Butler, MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 66:571–591. https://doi.org/10.1038/ja.2013.86.
12. World, Health Organization. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland.
13. Houghton, F. 2017. Antimicrobial resistance (AMR) and the United Nations (UN). J Infect Public Health 10:139–140. https://doi.org/10.1016/j.jiph.2016.10.002.
14. Boucher, HW, Bakken JS, Murray BE. 2016. The, United Nations and the urgent need for coordinated global action in the fight against antimicrobial resistance. Ann Intern Med 165:812–813. https://doi.org/10.7326/M16-2079.
15. Laxminarayan, R, Sridhar D, Blaser M, Wang M, Woolhouse M. 2016. Achieving global targets for antimicrobial resistance. Science 353: 874–875. https://doi.org/10.1126/science.aaf9286.
16. Gilbert, DN, Guidos RJ, Boucher HW, Talbot GH, Spellberg B, Edwards JE, Jr, Scheld MW, Bradley JS, Bartlett JG. 2010. The 10 × ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin, Infect Dis 50:1081–1083. https://doi.org/10.1086/652237.
17. Boucher, HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D. 2013. 10 × ‘20 progress— development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694. https://doi.org/10.1093/cid/cit152.
18. Silver, LL. 2016. A Gestalt approach to Gram-negative entry. Bioorg Med Chem 24:6379–6389. https://doi.org/10.1016/j.bmc.2016.06.044.
19. Gutsmann, T, Seydel U. 2010. Impact of the glycostructure of amphiphilic membrane components on the function of the outer membrane of Gram-negative bacteria as a matrix for incorporated channels and a target for antimicrobial peptides or proteins. Eur J Cell Biol 89:11–23. https://doi.org/10.1016/j.ejcb.2009.10.011.
20. Wu, EL, Engstrom O, Jo S, Stuhlsatz D, Yeom MS, Klauda JB, Widmalm G, Im W. 2013. Molecular dynamics and NMR spectroscopy studies of E. coli lipopolysaccharide structure and dynamics. Biophys J 105: 1444–1455. https://doi.org/10.1016/j.bpj.2013.08.002.
21. Khalid, S, Berglund NA, Holdbrook DA, Leung YM, Parkin J. 2015. The membranes of Gram-negative bacteria: progress in molecular modelling and simulation. Biochem Soc Trans 43:162–167. https://doi.org/10.1042/BST20140262.
22. Piggot, TJ, Holdbrook DA, Khalid S. 2011. Electroporation of the E. coli and S. Aureus membranes: molecular dynamics simulations of complex bacterial membranes. J Phys Chem B 115:13381–13388. https://doi.org/10.1021/jp207013v.
23. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382–388. https://doi.org/10.1126/science.8153625.
24. Kucharska, I, Liang B, Ursini N, Tamm LK. 2016. Molecular interactions of lipopolysaccharide with an outer membrane protein from Pseudomonas aeruginosa probed by solution NMR. Biochemistry 55:5061–5072. https://doi.org/10.1021/acs.biochem.6b00630.
25. Kowata, H, Tochigi S, Kusano T, Kojima S. 2016. Quantitative measurement of the outer membrane permeability in Escherichia coli lpp and tol-pal mutants defines the significance of Tol-Pal function for maintaining drug resistance. J Antibiot (Tokyo) 69:863–870. https://doi.org/10.1038/ja.2016.50.
26. Vaara, M, Plachy WZ, Nikaido H. 1990. Partitioning of hydrophobic probes into lipopolysaccharide bilayers. Biochim Biophys Acta 1024: 152–158. https://doi.org/10.1016/0005-2736(90)90218-D.
27. Needham, BD, Trent MS. 2013. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. Nat Rev Microbiol 11: 467–481. https://doi.org/10.1038/nrmicro3047.
28. Breidenstein, EBM, de la Fuente-Nunez C, Hancock REW. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19:419–426. https://doi.org/10.1016/j.tim.2011.04.005.
29. Butler, MS, Hansford KA, Blaskovich MAT, Halai R, Cooper MA. 2014. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo) 67: 631–644. https://doi.org/10.1038/ja.2014.111.
30. Boger, D. 2001. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev 21:356–381. https://doi.org/10.1002/med.1014.
31. Silver, LL. 2008. Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opin Drug Discov 3:487–500. https://doi.org/10.1517/17460441.3.5.487.
32. Oldham, ML, Chen S, Chen J. 2013. Structural basis for substrate specificity in the Escherichia coli maltose transport system. Proc Natl Acad Sci U S A 110:18132–18137. https://doi.org/10.1073/pnas.1311407110.
33. Ning, X, Lee S, Wang Z, Kim D, Stubblefield B, Gilbert E, Murthy N. 2011. Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. Nat Mater 10:602–607. https://doi.org/10.1038/nmat3074.
34. Fairman, JW, Noinaj N, Buchanan SK. 2011. The structural biology of beta-barrel membrane proteins: a summary of recent reports. Curr Opin Struct Biol 21:523–531. https://doi.org/10.1016/j.sbi.2011.05.005.
35. Zeth, K, Thein M. 2010. Porins in prokaryotes and eukaryotes: common themes and variations. Biochem J 431:13–22. https://doi.org/10.1042/BJ20100371.
36. Cowan, SW, Schirmer T, Rummel G, Steiert M, Ghosh R, Pauptit RA, Jansonius JN, Rosenbusch JP. 1992. Crystal structures explain functional properties of two E. coli porins. Nature 358:727–733. https://doi.org/10.1038/358727a0.
37. Delcour, AH. 2009. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 1794:808–816. https://doi.org/10.1016/j.bbapap.2008.11.005.
38. Nakae, T. 1975. Outer membrane of Salmonella typhimurium: reconstitution of sucrose-permeable membrane vesicles. Biochem Biophys Res Commun 64:1224–1230. https://doi.org/10.1016/0006-291X(75)90823-2.
39. Nikaido, H. 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593–656. https://doi.org/10.1128/MMBR.67.4.593-656.2003.
40. Hancock, RE, Decad GM, Nikaido H. 1979. Identification of the protein producing transmembrane diffusion pores in the outer membrane of Pseudomonas aeruginosa PA01. Biochim, Biophys Acta 554:323–331. https://doi.org/10.1016/0005-2736(79)90373-0.
41. Chevalier, S, Bouffartigues E, Bodilis J, Maillot O, Lesouhaitier O, Feuilloley MGJ, Orange N, Dufour A, Cornelis P. 2017. Structure, function and regulation of Pseudomonas aeruginosa porins. FEMS Microbiol Rev 41:698–722. https://doi.org/10.1093/femsre/fux020.
42. Nikaido, H, Nikaido K, Harayama S. 1991. Identification and characterization of porins in Pseudomonas aeruginosa. J Biol Chem 266: 770–779.
43. Hancock, RE. 1998. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 27(Suppl 1):S93–S99. https://doi.org/10.1086/514909.
44. Yoshimura, F, Zalman LS, Nikaido H. 1983. Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem 258:2308–2314.
45. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock REW, Martinez JL. 2011. The intrinsic resistome of Pseudomonas aeruginosa to betalactams. Virulence 2:144–146. https://doi.org/10.4161/viru.2.2.15014.
46. Hancock, RE, Farmer SW, Li ZS, Poole K. 1991. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob Agents Chemother 35: 1309–1314. https://doi.org/10.1128/AAC.35.7.1309.
47. Hancock, RE. 1984. Alterations in outer membrane permeability. Annu Rev Microbiol 38:237–264. https://doi.org/10.1146/annurev.mi.38.100184.001321.
48. Arunmanee, W, Pathania M, Solovyova AS, Le Brun AP, Ridley H, Basle A, van den Berg B, Lakey JH. 2016. Gram-negative trimeric porins have specific LPS binding sites that are essential for porin biogenesis. Proc Natl Acad Sci U S A 113:E5034–E5043. https://doi.org/10.1073/pnas.1602382113.
49. Clifton, LA, Skoda MWA, Le Brun AP, Ciesielski F, Kuzmenko I, Holt SA, Lakey JH. 2015. Effect of divalent cation removal on the structure of gram-negative bacterial outer membrane models. Langmuir 31: 404–412. https://doi.org/10.1021/la504407v.
50. Herrmann, M, Schneck E, Gutsmann T, Brandenburg K, Tanaka M. 2015. Bacterial lipopolysaccharides form physically cross-linked, twodimensional gels in the presence of divalent cations. Soft Matter 11: 6037–6044. https://doi.org/10.1039/C5SM01002K.
51. George, S, Hamblin MR, Kishen A. 2009. Uptake pathways of anionic and cationic photosensitizers into bacteria. Photochem Photobiol Sci 8:788–795. https://doi.org/10.1039/b809624d.
52. Hancock, RE, Bell A. 1988. Antibiotic uptake into gram-negative bacteria. Eur J Clin Microbiol Infect Dis 7:713–720. https://doi.org/10.1007/BF01975036.
53. Nicas, TI, Hancock RE. 1980. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 143:872–878.
54. Zimelis, VM, Jackson GG. 1973. Activity of aminoglycoside antibiotics against Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis 127:663–669. https://doi.org/10.1093/infdis/127.6.663.
55. Davis, SD, Iannetta A, Wedgwood RJ. 1971. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis 124: 610–612. https://doi.org/10.1093/infdis/124.6.610.
56. Newton, BA. 1954. Site of action of polymyxin on Pseudomonas aeruginosa: antagonism by cations. J Gen Microbiol 10:491–499. https://doi.org/10.1099/00221287-10-3-491.
57. Hancock, RE, Wong PG. 1984. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26:48–52. https://doi.org/10.1128/AAC.26.1.48.
58. Tamber, S, Hancock REW. 2003. On the mechanism of solute uptake in Pseudomonas. Front Biosci 8:s472–s483. https://doi.org/10.2741/1075.
59. Farha, MA, Verschoor CP, Bowdish D, Brown ED. 2013. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem Biol 20:1168–1178. https://doi.org/10.1016/j.chembiol.2013.07.006.
60. Chopra, I. 1988. Molecular mechanisms involved in the transport of antibiotics into bacteria. Parasitology 96(Suppl):S25–S44. https://doi.org/10.1017/S0031182000085966.
61. Shultis, DD, Purdy MD, Banchs CN, Wiener MC. 2006. Outer membrane active transport: structure of the BtuB:TonB complex. Science 312: 1396–1399. https://doi.org/10.1126/science.1127694.
62. Kashket, ER. 1985. The proton motive force in bacteria: a critical assessment of methods. Annu Rev Microbiol 39:219–242. https://doi.org/10.1146/annurev.mi.39.100185.001251.
63. Zarfl, C, Matthies M, Klasmeier J. 2008. A mechanistical model for the uptake of sulfonamides by bacteria. Chemosphere 70:753–760. https://doi.org/10.1016/j.chemosphere.2007.07.045.
64. Yamaguchi, A, Ohmori H, Kaneko-Ohdera M, Nomura T, Sawai T. 1991. Delta pH-dependent accumulation of tetracycline in Escherichia coli. Antimicrob Agents Chemother 35:53–56. https://doi.org/10.1128/AAC.35.1.53.
65. Taber, HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 51:439–457.
66. Zgurskaya, HI, Lopez CA, Gnanakaran S. 2015. Permeability barrier of Gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis 1:512–522. https://doi.org/10.1021/acsinfecdis.5b00097.
67. Li, X-Z, Plesiat P, Nikaido H. 2015. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28:337–418. https://doi.org/10.1128/CMR.00117-14.
68. Song, S, Kim J-S, Lee K, Ha N-C. 2015. Molecular architecture of the bacterial tripartite multidrug efflux pump focusing on the adaptor bridging model. J Microbiol 53:355–364. https://doi.org/10.1007/s12275-015-5248-4.
69. Delmar, JA, Su C-C, Yu EW. 2014. Bacterial multidrug efflux transporters. Annu Rev Biophys 43:93–117. https://doi.org/10.1146/annurev-biophys-051013-022855.
70. Kumar, S, Varela MF. 2012. Biochemistry of bacterial multidrug efflux pumps. Int J Mol Sci 13:4484–4495. https://doi.org/10.3390/ijms13044484.
71. Nikaido, H. 2009. Multidrug resistance in bacteria. Annu Rev Biochem 78:119–146. https://doi.org/10.1146/annurev.biochem.78.082907.145923.
72. Piddock, LJV. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19: 382–402. https://doi.org/10.1128/CMR.19.2.382-402.2006.
73. Singh, SB, Young K, Silver LL. 2017. What is an “ideal” antibiotic? Discovery challenges and path forward. Biochem Pharmacol 133:63–73. https://doi.org/10.1016/j.bcp.2017.01.003.
74. Lipinski, CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3–26. https://doi.org/10.1016/S0169-409X(00)00129-0.
75. Lipinski, CA. 2016. Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev 101:34–41. https://doi.org/10.1016/j.addr.2016.04.029.
76. Ebejer, J-P, Charlton MH, Finn PW. 2016. Are the physicochemical properties of antibacterial compounds really different from other drugs? J Cheminform 8:30. https://doi.org/10.1186/s13321-016-0143-5.
77. O’Shea R, Moser HE. 2008. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51: 2871–2878. https://doi.org/10.1021/jm700967e.
78. Takrouri, K, Cooper HD, Spaulding A, Zucchi P, Koleva B, Cleary DC, Tear W, Beuning PJ, Hirsch EB, Aggen JB. 2016. Progress against Escherichia coli with the oxazolidinone class of antibacterials: test case for a general approach to improving whole-cell Gram-negative activity. ACS Infect Dis 2:405–426. https://doi.org/10.1021/acsinfecdis.6b00003.
79. Schumacher, A, Trittler R, Bohnert JA, Kummerer K, Pages J-M, Kern WV. 2007. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother 59:1261–1264. https://doi.org/10.1093/jac/dkl380.
80. Zhou, Y, Joubran C, Miller-Vedam L, Isabella V, Nayar A, Tentarelli S, Miller A. 2015. Thinking outside the “bug”: a unique assay to measure intracellular drug penetration in gram-negative bacteria. Anal Chem 87:3579–3584. https://doi.org/10.1021/ac504880r.
81. Bhat, J, Narayan A, Venkatraman J, Chatterji M. 2013. LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: linking compound levels to cellular potency. J Microbiol Methods 94:152–158. https://doi.org/10.1016/j.mimet.2013.05.010.
82. Heidari-Torkabadi H, Che T, Lombardo MN, Wright DL, Anderson AC, Carey PR. 2015. Measuring propargyl-linked drug populations inside bacterial cells, and their interaction with a dihydrofolate reductase target, by Raman microscopy. Biochemistry 54:2719–2726. https://doi.org/10.1021/acs.biochem.5b00202.
83. Cinquin, B, Maigre L, Pinet E, Chevalier J, Stavenger RA, Mills S, Refregiers M, Pages J-M. 2015. Microspectrometric insights on the uptake of antibiotics at the single bacterial cell level. Sci Rep 5:17968. https://doi.org/10.1038/srep17968.
84. Davis, TD, Gerry CJ, Tan DS. 2014. General platform for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem Biol 9:2535–2544. https://doi.org/10.1021/cb5003015.
85. Richter, MF, Drown BS, Riley AP, Garcia A, Shirai T, Svec RL, Hergenrother PJ. 2017. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545:299–304. https://doi.org/10.1038/nature22308.
86. Hurdle, JG, O’Neill AJ, Chopra I, Lee RE. 2011. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9:62–75. https://doi.org/10.1038/nrmicro2474.
87. Ghosh, C, Haldar J. 2015. Membrane-active small molecules: designs inspired by antimicrobial peptides. ChemMedChem 10:1606–1624. https://doi.org/10.1002/cmdc.201500299.
88. Herzog, IM, Fridman M. 2014. Design and synthesis of membranetargeting antibiotics: from peptides- to aminosugar-based antimicrobial cationic amphiphiles. Medchemcomm 5:1014–1026. https://doi.org/10.1039/C4MD00012A.
89. Domalaon, R, Zhanel GG, Schweizer F. 2016. Short antimicrobial peptides and peptide scaffolds as promising antibacterial agents. Curr Top Med Chem 16:1217–1230. https://doi.org/10.2174/1568026615666150915112459.
90. Benhamou, RI, Shaul P, Herzog IM, Fridman M. 2015. Di-N-methylation of anti-Gram-positive aminoglycoside-derived membrane disruptors improves antimicrobial potency and broadens spectrum to Gramnegative bacteria. Angew Chem Int Ed Engl 54:13617–13621. https://doi.org/10.1002/anie.201506814.
91. Cigana, C, Bernardini F, Facchini M, Alcala-Franco B, Riva C, De Fino I, Rossi A, Ranucci S, Misson P, Chevalier E, Brodmann M, Schmitt M, Wach A, Dale GE, Obrecht D, Bragonzi A. 2016. Efficacy of the novel antibiotic POL7001 in preclinical models of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother 60:4991–5000. https://doi.org/10.1128/AAC.00390-16.
92. Srinivas, N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RLA, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Kach A, Eberl L, Riedel K, DeMarco SJ, Robinson JA. 2010. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010–1013. https://doi.org/10.1126/science.1182749.
93. Cohen, NR, Lobritz MA, Collins JJ. 2013. Microbial persistence and the road to drug resistance. Cell Host Microbe 13:632–642. https://doi.org/10.1016/j.chom.2013.05.009.
94. Certain, LK, Way JC, Pezone MJ, Collins JJ. 2017. Using engineered bacteria to characterize infection dynamics and antibiotic effects in vivo. Cell Host Microbe 22:263.e4–268.e4. https://doi.org/10.1016/j.chom.2017.08.001.
95. Oz, T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, Ozan VB, Senturk GH, Cokol M, Yeh P, Toprak E. 2014. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol 31:2387–2401. https://doi.org/10.1093/molbev/msu191.
96. Pál, C, Papp B, Lázár V. 2015. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol 23:401–407. https://doi.org/10.1016/j.tim.2015.02.009.
97. Barlow, M. 2009. What antimicrobial resistance has taught us about horizontal gene transfer. Methods Mol Biol 532:397–411. https://doi.org/10.1007/978-1-60327-853-9_23.
98. Williams, SCP. 2014. News feature: next-generation antibiotics. Proc Natl Acad Sci U S A 111:11227–11229. https://doi.org/10.1073/pnas.1413117111.
99. Brannon, JR, Hadjifrangiskou M. 2016. The arsenal of pathogens and antivirulence therapeutic strategies for disarming them. Drug Des Devel Ther 10:1795–1806. https://doi.org/10.2147/DDDT.S98939.
100. Dickey, SW, Cheung GYC, Otto M. 2017. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov 16:457–471. https://doi.org/10.1038/nrd.2017.23.
101. Rampioni, G, Leoni L, Williams P. 2014. The art of antibacterial warfare: deception through interference with quorum sensing-mediated communication. Bioorg Chem 55:60–68. https://doi.org/10.1016/j.bioorg.2014.04.005.
102. Asfahl, KL, Schuster M. 2017. Social interactions in bacterial cell-cell signaling. FEMS Microbiol Rev 41:92–107. https://doi.org/10.1093/femsre/fuw038.
103. Grandclement, C, Tannieres M, Morera S, Dessaux Y, Faure D. 2016. Quorum quenching: role in nature and applied developments. FEMS Microbiol Rev 40:86–116. https://doi.org/10.1093/femsre/fuv038.
104. Lee, J, Zhang L. 2015. The hierarchy quorum sensing network in Pseudomonas aeruginosa. Protein Cell 6:26–41. https://doi.org/10.1007/s13238-014-0100-x.
105. Papenfort, K, Bassler BL. 2016. Quorum sensing signal-response systems in Gram-negative bacteria. Nat Rev Microbiol 14:576–588. https://doi.org/10.1038/nrmicro.2016.89.
106. Maura, D, Ballok AE, Rahme LG. 2016. Considerations and caveats in anti-virulence drug development. Curr Opin Microbiol 33:41–46. https://doi.org/10.1016/j.mib.2016.06.001.
107. Singh, RP, Desouky SE, Nakayama J. 2016. Quorum quenching strategy targeting Gram-positive pathogenic bacteria. Adv Exp Med Biol 901: 109–130. https://doi.org/10.1007/5584_2016_1.
108. Zambelloni, R, Marquez R, Roe AJ. 2015. Development of antivirulence compounds: a biochemical review. Chem Biol Drug Des 85:43–55. https://doi.org/10.1111/cbdd.12430.
109. O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. 2013. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci U S A 110:17981–17986. https://doi.org/10.1073/pnas.1316981110.
110. Miller, LC, O’Loughlin CT, Zhang Z, Siryaporn A, Silpe JE, Bassler BL, Semmelhack MF. 2015. Development of potent inhibitors of pyocyanin production in Pseudomonas aeruginosa. J Med Chem 58:1298–1306. https://doi.org/10.1021/jm5015082.
111. Simonetti, O, Cirioni O, Cacciatore I, Baldassarre L, Orlando F, Pierpaoli E, Lucarini G, Orsetti E, Provinciali M, Fornasari E, Di Stefano A, Giacometti A, Offidani A. 2016. Efficacy of the quorum sensing inhibitor FS10 alone and in combination with tigecycline in an animal model of Staphylococcal infected wound. PLoS One 11:e0151956. https://doi.org/10.1371/journal.pone.0151956.
112. Alasil, SM, Omar R, Ismail S, Yusof MY. 2015. Inhibition of quorum sensing-controlled virulence factors and biofilm formation in Pseudomonas aeruginosa by culture extract from novel bacterial species of Paenibacillus using a rat model of chronic lung infection. Int J Bacteriol 2015:671562. https://doi.org/10.1155/2015/671562.
113. Oh, K-B, Nam K-W, Ahn H, Shin J, Kim S, Mar W. 2010. Therapeutic effect of (Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) against Staphylococcus aureus infection in a murine model. Biochem Biophys Res Commun 396:440–444. https://doi.org/10.1016/j.bbrc.2010.04.113.
114. Lidor, O, Al-Quntar A, Pesci EC, Steinberg D. 2015. Mechanistic analysis of a synthetic inhibitor of the Pseudomonas aeruginosa LasI quorumsensing signal synthase. Sci Rep 5:16569. https://doi.org/10.1038/srep16569.
115. Kalia, VC, Wood TK, Kumar P. 2014. Evolution of resistance to quorumsensing inhibitors. Microb Ecol 68:13–23. https://doi.org/10.1007/s00248-013-0316-y.
116. Scutera, S, Zucca M, Savoia D. 2014. Novel approaches for the design and discovery of quorum-sensing inhibitors. Expert Opin Drug Discov 9:353–366. https://doi.org/10.1517/17460441.2014.894974.
117. Garcia-Contreras R, Martinez-Vazquez M, Velazquez Guadarrama N, Villegas Paneda AG, Hashimoto T, Maeda T, Quezada H, Wood TK. 2013. Resistance to the quorum-quenching compounds brominated furanone C-30 and 5-fluorouracil in Pseudomonas aeruginosa clinical isolates. Pathog Dis 68:8–11. https://doi.org/10.1111/2049-632X.12039.
118. Hilf, M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. 1989. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 87:540–546. https://doi.org/10.1016/S0002-9343(89)80611-4.
119. Wright, GD. 2016. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol 24:862–871. https://doi.org/10.1016/j.tim.2016.06.009.
120. White, AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. 2004. Augmentin (amoxicillin/clavulanate) in the treatment of communityacquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 53:i3–i20. https://doi.org/10.1093/jac/dkh050.
121. Drawz, SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160–201. https://doi.org/10.1128/CMR.00037-09.
122. Gniadkowski, M. 2001. Evolution and epidemiology of extendedspectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 7:597–608. https://doi.org/10.1046/j.1198-743x.2001.00330.x.
123. Paterson, DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686. https://doi.org/10.1128/CMR.18.4.657-686.2005.
124. Ball, P. 2007. Conclusions: the future of antimicrobial therapy— Augmentin and beyond. Int J Antimicrob Agents 30(Suppl 2): S139–S141. https://doi.org/10.1016/j.ijantimicag.2007.08.016.
125. Geddes, AM, Klugman KP, Rolinson GN. 2007. Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents 30(Suppl 2):S109–S112. https://doi.org/10.1016/j.ijantimicag.2007.07.015.
126. Taneja, N, Kaur H. 2016. Insights into newer antimicrobial agents against Gram-negative bacteria. Microbiol Insights 9:9–19. https://doi.org/10.4137/MBI.S29459.
127. Butler, MS, Blaskovich MA, Cooper MA. 2017. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot (Tokyo) 70:3–24. https://doi.org/10.1038/ja.2016.72.
128. Gill, EE, Franco OL, Hancock REW. 2015. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des 85:56–78. https://doi.org/10.1111/cbdd.12478.
129. Pieren, M, Tigges M. 2012. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr Opin Pharmacol 12:551–555. https://doi.org/10.1016/j.coph.2012.07.005.
130. Kalan, L, Wright GD. 2011. Antibiotic adjuvants: multicomponent antiinfective strategies. Expert Rev Mol Med 13:e5. https://doi.org/10.1017/S1462399410001766.
131. Jacobs, RF. 1986. Imipenem-cilastatin: the first thienamycin antibiotic. Pediatr Infect Dis 5:444–448. https://doi.org/10.1097/00006454-198607000-00015.
132. Hikida, M, Kawashima K, Yoshida M, Mitsuhashi S. 1992. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 30:129–134. https://doi.org/10.1093/jac/30.2.129.
133. Hori, Y, Aoki N, Kuwahara S, Hosojima M, Kaseda R, Goto S, Iida T, De S, Kabasawa H, Kaneko R, Aoki H, Tanabe Y, Kagamu H, Narita I, Kikuchi T, Saito A. 2017. Megalin blockade with cilastatin suppresses druginduced nephrotoxicity. J Am Soc Nephrol 28:1783–1791. https://doi.org/10.1681/ASN.2016060606.
134. Falagas, ME, Mavroudis AD, Vardakas KZ. 2016. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect? Expert Rev Anti Infect Ther 14:747–763. https://doi.org/10.1080/14787210.2016.1204911.
135. Blizzard, TA, Chen H, Kim S, Wu J, Bodner R, Gude C, Imbriglio J, Young K, Park Y-W, Ogawa A, Raghoobar S, Hairston N, Painter RE, Wisniewski D, Scapin G, Fitzgerald P, Sharma N, Lu J, Ha S, Hermes J, Hammond ML. 2014. Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin. Bioorg Med Chem Lett 24:780–785. https://doi.org/10.1016/j.bmcl.2013.12.101.
136. Lucasti, C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. 2016. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234–6243. https://doi.org/10.1128/AAC.00633-16.
137. King, AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR, Coombes BK, Wright GD. 2014. Aspergillomarasmine, A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510: 503–506. https://doi.org/10.1038/nature13445.
138. Haenni, AL, Robert M, Vetter W, Roux L, Barbier M, Lederer E. 1965. Chemical structure of aspergillomarasmines A and B. Helv Chim Acta 48:729–750. https://doi.org/10.1002/hlca.19650480409.
139. Arai, K, Ashikawa N, Nakakita Y, Matsuura A, Ashizawa N, Munekata M. 1993. Aspergillomarasmine, A and B, potent microbial inhibitors of endothelin-converting enzyme. Biosci Biotechnol Biochem 57: 1944–1945. https://doi.org/10.1271/bbb.57.1944.
140. Matsuura, A, Okumura H, Asakura R, Ashizawa N, Takahashi M, Kobayashi F, Ashikawa N, Arai K. 1993. Pharmacological profiles of aspergillomarasmines as endothelin converting enzyme inhibitors. Jpn J Pharmacol 63:187–193. https://doi.org/10.1254/jjp.63.187.
141. Karsisiotis, AI, Damblon CF, Roberts GCK. 2014. A variety of roles for versatile zinc in metallo-beta-lactamases. Metallomics 6:1181–1197. https://doi.org/10.1039/C4MT00066H.
142. Meini, M-R, Llarrull LI, Vila AJ. 2015. Overcoming differences: the catalytic mechanism of metallo-beta-lactamases. FEBS Lett 589:3419–3432. https://doi.org/10.1016/j.febslet.2015.08.015.
143. Koteva, K, King AM, Capretta A, Wright GD. 2016. Total synthesis and activity of the metallo-beta-lactamase inhibitor aspergillomarasmine A. Angew Chem Int Ed Engl 55:2210–2212. https://doi.org/10.1002/anie.201510057.
144. Albu, SA, Koteva K, King AM, Al-Karmi S, Wright GD, Capretta A. 2016. Total synthesis of aspergillomarasmine A and related compounds: a sulfamidate approach enables exploration of structure-activity relationships. Angew Chem Int Ed Engl 55:13259–13262. https://doi.org/10.1002/anie.201606657.
145. Liao, D, Yang S, Wang J, Zhang J, Hong B, Wu F, Lei X. 2016. Total synthesis and structural reassignment of aspergillomarasmine A. Angew Chem Int Ed Engl 55:4291–4295. https://doi.org/10.1002/anie.201509960.
146. Zabawa, TP, Pucci MJ, Parr TR, Jr, Lister T. 2016. Treatment of Gramnegative bacterial infections by potentiation of antibiotics. Curr Opin Microbiol 33:7–12. https://doi.org/10.1016/j.mib.2016.05.005.
147. Pogliano, J, Sharp M, Lister T, Rubio A. 2016. Bacterial cytological profiling of SPR741 mechanism of action is consistent with membrane permeabilization that allows penetration of antibiotics into Gramnegative (G-) bacteria, abstr P493. Abstr, ASM Microbe 2016.
148. Corbett, D, Wise A, Birchall S, Trimby E, Smith J, Lister T, Vaara M. 2016. Potentiation of antibiotic activity by a novel cationic peptide, SPR741, abstr P492. Abstr, ASM Microbe 2016.
149. Corbett, D, Wise A, Langley T, Skinner K, Trimby E, Birchall S, Dorali A, Sandiford S, Williams J, Warn P, Vaara M, Lister T. 2017. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob, Agents Chemother 61:e00200-17. https://doi.org/10.1128/AAC.00200-17.
150. Vaara, M, Siikanen O, Apajalahti J, Fox J, Frimodt-Moller N, He H, Poudyal A, Li J, Nation RL, Vaara T. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 54:3341–3346. https://doi.org/10.1128/AAC.01439-09.
151. Warn, P, Teague J, Burgess E, Payne L, Corbett D, Sharp A, Lister T, Parr TR, Jr. 2016. In vivo efficacy of combinations of novel antimicrobial peptide SPR741 and rifampicin in short-duration murine lung infection models of K. pneumoniae or E. cloacae infection, abstr P497. Abstr, ASM Microbe 2016.
152. Warn, P, Thommes P, Vaddi S, Corbett D, Coles D, Vaccaro L, Lister T, Parr TR, Jr. 2016. In vivo efficacy of combinations of novel antimicrobial peptide SPR741 and rifampicin in short-duration murine thigh infection models of Gram-negative bacterial infection, abstr P561. Abstr, ASM Microbe 2016.
153. Zavascki, AP, Nation RL. 2017. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother 61:e02319-16. https://doi.org/10.1128/AAC.02319-16.
154. Pogue, JM, Ortwine JK, Kaye KS. 2016. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? Int J Antimicrob Agents 48:622–626. https://doi.org/10.1016/j.ijantimicag.2016.11.001.
155. Coleman, S, Bleavins M, Lister T, Vaara M, Parr TR, Jr. 2016. The assessment of SPR741 for nephrotoxicity in cynomolgus monkeys and Sprague-Dawley rats, abstr P523. Abstr, ASM Microbe 2016.
156. Huovinen, P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 32:1608–1614. https://doi.org/10.1086/320532.
157. Masters, PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. 2003. Trimethoprimsulfamethoxazole revisited. Arch Intern Med 163:402–410. https://doi.org/10.1001/archinte.163.4.402.
158. McIsaac WJ, Prakash P, Ross S. 2008. The management of acute uncomplicated cystitis in adult women by family physicians in Canada. Can J Infect Dis Med Microbiol 19:287-293.
159. Libecco, JA, Powell KR. 2004. Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev 25:375–380.
160. Livermore, DM, Mushtaq S, Warner M, Woodford N. 2014. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/ trimethoprim and other agents against multiresistant Gram-negative bacteria. J Antimicrob Chemother 69:1050–1056. https://doi.org/10.1093/jac/dkt455.
161. Falagas, ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654–663. https://doi.org/10.1128/AAC.01222-13.
162. Kmeid, JG, Youssef MM, Kanafani ZA, Kanj SS. 2013. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther 11:1355–1362. https://doi.org/10.1586/14787210.2013.846215.
163. Marcus, R, Paul M, Elphick H, Leibovici L. 2011. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 37:491–503. https://doi.org/10.1016/j.ijantimicag.2010.11.029.
164. Vardakas, KZ, Tansarli GS, Bliziotis IA, Falagas ME. 2013. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 41:301–310. https://doi.org/10.1016/j.ijantimicag.2012.12.006.
165. Chamot, E, Boffi El Amari E, Rohner P, Van Delden C. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47:2756–2764. https://doi.org/10.1128/AAC.47.9.2756-2764.2003.
166. Falagas, ME, Matthaiou DK, Bliziotis IA. 2006. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 57:639–647. https://doi.org/10.1093/jac/dkl044.
167. Poulikakos, P, Tansarli GS, Falagas ME. 2014. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33:1675–1685. https://doi.org/10.1007/s10096-014-2124-9.
168. Tamma, PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25:450–470. https://doi.org/10.1128/CMR.05041-11.
169. Hamilton-Miller JM. 1994. Dual-action antibiotic hybrids. J Antimicrob Chemother 33:197–200. https://doi.org/10.1093/jac/33.2.197.
170. Bremner, JB, Ambrus JI, Samosorn S. 2007. Dual action-based approaches to antibacterial agents. Curr Med Chem 14:1459–1477. https://doi.org/10.2174/092986707780831168.
171. Karoli, T, Mamidyala SK, Zuegg J, Fry SR, Tee EHL, Bradford TA, Madala PK, Huang JX, Ramu S, Butler MS, Cooper MA. 2012. Structure aided design of chimeric antibiotics. Bioorg Med Chem Lett 22:2428–2433. https://doi.org/10.1016/j.bmcl.2012.02.019.
172. Basak, A, Pal R. 2005. Synthesis of beta-lactam nucleoside chimera via Kinugasa reaction and evaluation of their antibacterial activity. Bioorg Med Chem Lett 15:2015–2018. https://doi.org/10.1016/j.bmcl.2005.02.064.
173. Blais, J, Lewis SR, Krause KM, Benton BM. 2012. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother 56:1584–1587. https://doi.org/10.1128/AAC.05532-11.
174. Long, DD, Aggen JB, Christensen BG, Judice JK, Hegde SS, Kaniga K, Krause KM, Linsell MS, Moran EJ, Pace JL. 2008. A multivalent approach to drug discovery for novel antibiotics. J Antibiot (Tokyo) 61:595–602. https://doi.org/10.1038/ja.2008.79.
175. Liang, C-H, Romero A, Rabuka D, Sgarbi PWM, Marby KA, Duffield J, Yao S, Cheng ML, Ichikawa Y, Sears P, Hu C, Hwang S-B, Shue Y-K, Sucheck SJ. 2005. Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. Bioorg Med Chem Lett 15:2123–2128. https://doi.org/10.1016/j.bmcl.2005.02.029.
176. Kline, T, Fromhold M, McKennon TE, Cai S, Treiberg J, Ihle N, Sherman D, Schwan W, Hickey MJ, Warrener P, Witte PR, Brody LL, Goltry L, Barker LM, Anderson SU, Tanaka SK, Shawar RM, Nguyen LY, Langhorne M, Bigelow A, Embuscado L, Naeemi E. 2000. Antimicrobial effects of novel siderophores linked to beta-lactam antibiotics. Bioorg Med Chem 8:73–93. https://doi.org/10.1016/S0968-0896(99)00261-8.
177. Becker, B, Cooper MA. 2013. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 8:105–115. https://doi.org/10.1021/cb3005116.
178. Brötz-Oesterhelt H, Brunner NA. 2008. How many modes of action should an antibiotic have? Curr Opin Pharmacol 8:564–573. https://doi.org/10.1016/j.coph.2008.06.008.
179. Wermuth, CG, Ganellin CR, Lindberg P, Mitscher LA. 1998. Glossary of terms used in medicinal chemistry (IUPAC recommendations 1998). Pure Appl Chem 70:1129–1143. https://doi.org/10.1351/pac199870051129.
180. Preobrazhenskaya, AN, Olsufyeva EN, Preyobrazhenskaya MN. 2015. Design of dual action antibiotics as an approach to search for new promising drugs. Russ Chem Rev 84:61. https://doi.org/10.1070/RCR4448.
181. Brown, DG, Bostrom J. 2016. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? J Med Chem 59:4443–4458. https://doi.org/10.1021/acs.jmedchem.5b01409.
182. Sabath, LD, Jago M, Abraham EP. 1965. Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea. Biochem J 96:739–752. https://doi.org/10.1042/bj0960739.
183. Bryskier, A. 1997. Review dual β-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment. Expert Opin Invest Drugs 6:1479–1499. https://doi.org/10.1517/13543784.6.10.1479.
184. Smyth, TP, O’Donnell ME, O’Connor MJ, St Ledger JO. 1998. S-Aminosulfeniminopenicillins: multimode β-lactamase inhibitors and template structures for penicillin-based β-lactamase substrates as prodrugs. J Org Chem 63:7600–7618. https://doi.org/10.1021/jo970737f.
185. Smyth, TP, O’Donnell ME, O’Connor MJ, St Ledger JO. 2000. β-Lactamase-dependent prodrugs—recent developments. Tetrahedron 56:5699–5707. https://doi.org/10.1016/S0040-4020(00)00419-1.
186. Ruddle, CC, Smyth TP. 2004. Penicillins as beta-lactamase-dependent prodrugs: enabling role of a vinyl ester exocyclic to the lactam ring. Chem Commun (Camb) 2004:2332–2333. https://doi.org/10.1039/B409517K.
187. Maltezou, HC. 2009. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 33: 405.e1–405.e7. https://doi.org/10.1016/j.ijantimicag.2008.09.003.
188. O’Callaghan CH, Sykes RB, Staniforth SE. 1976. A new cephalosporin with a dual mode of action. Antimicrob Agents Chemother 10:245–248. https://doi.org/10.1128/AAC.10.2.245.
189. Dinning, AJ, Al-Adham IS, Eastwood IM, Austin P, Collier PJ. 1998. Pyrithione biocides as inhibitors of bacterial ATP synthesis. J Appl Microbiol 85:141–146. https://doi.org/10.1046/j.1365-2672.1998.00478.x.
190. Mobashery, S, Johnston M. 1987. Inactivation of alanine racemase by beta-chloro-L-alanine released enzymatically from amino acid and peptide C10-esters of deacetylcephalothin. Biochemistry 26:5878–5884. https://doi.org/10.1021/bi00392a045.
191. Mobashery, S, Lerner SA, Johnston M. 1986. Conscripting betalactamase for use in drug delivery Synthesis and biological activity of a cephalosporin C10-ester of an antibiotic dipeptide. J Am Chem Soc 108:1685–1686. https://doi.org/10.1021/ja00267a045.
192. Li, Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Wahl GM, Lobl TJ, Chan MF. 2002. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against β-lactamase-producing strains. Antimicrob Agents Chemother 46: 1262–1268. https://doi.org/10.1128/AAC.46.5.1262-1268.2002.
193. Stone, GW, Zhang Q, Castillo R, Ramana V, Bueno AR, Lee JY, Li Q, Khambatta G, Nafsika H, Doppalapudi VR, Sergeeva M, Georgopapadakou NH. 2004. Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by β-lactamases. Antimicrob Agents Chemother 48: 477–483. https://doi.org/10.1128/AAC.48.2.477-483.2004.
194. Jones, RN, Barry AL, Thornsberry C. 1989. Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob Agents Chemother 33:944–950. https://doi.org/10.1128/AAC.33.6.944.
195. Georgopapadakou, NH, Bertasso A, Chan KK, Chapman JS, Cleeland R, Cummings LM, Dix BA, Keith DD. 1989. Mode of action of the dualaction cephalosporin Ro 23-9424. Antimicrob, Agents Chemother 33: 1067–1071. https://doi.org/10.1128/AAC.33.7.1067.
196. Pace, J, Bertasso A, Georgopapadakou NH. 1991. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424. Antimicrob, Agents Chemother 35:910–915. https://doi.org/10.1128/AAC.35.5.910.
197. Georgopapadakou, NH, Bertasso A. 1993. Mechanisms of action of cephalosporin 3=-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrob Agents Chemother 37:559–565. https://doi.org/10.1128/AAC.37.3.559.
198. Albrecht, HA, Beskid G, Chan KK, Christenson JG, Cleeland R, Deitcher KH, Georgopapadakou NH, Keith DD, Pruess DL, Sepinwall J, Specian AC, Jr, Then RL, Weigele M, West KF, Yang R. 1990. Cephalosporin 3=-quinolone esters with a dual mode of action. J Med Chem 33:77–86. https://doi.org/10.1021/jm00163a013.
199. Matera, G, Berlinghieri MC, Foti F, Barreca GS, Foca A. 1996. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. J Antimicrob Chemother 38:799–807. https://doi.org/10.1093/jac/38.5.799.
200. Christenson, JG, Chan KK, Cleeland R, Dix-Holzknecht B, Farrish HH, Patel IH, Specian A. 1990. Pharmacokinetics of Ro 23-9424, a dualaction cephalosporin, in animals. Antimicrob Agents Chemother 34: 1895–1900. https://doi.org/10.1128/AAC.34.10.1895.
201. Beskid, G, Siebelist J, McGarry CM, Cleeland R, Chan K, Keith DD. 1990. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin. Chemotherapy 36:109–116. https://doi.org/10.1159/000238756.
202. Silver, LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6:41–55. https://doi.org/10.1038/nrd2202.
203. Gu, JW, Neu HC. 1990. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics. Antimicrob Agents Chemother 34:189–195. https://doi.org/10.1128/AAC.34.2.189.
204. Chapman, JS, Bertasso A, Cummings LM, Georgopapadakou NH. 1995. Low-level resistance to the cephalosporin 3=-quinolone ester Ro 23- 9424 in Escherichia coli. Antimicrob Agents Chemother 39:564–566. https://doi.org/10.1128/AAC.39.2.564.
205. Ng, EY, Trucksis M, Hooper DC. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 38:1345–1355. https://doi.org/10.1128/AAC.38.6.1345.
206. Shapiro, S. 2013. Speculative strategies for new antibacterials: all roads should not lead to Rome. J Antibiot (Tokyo) 66:371–386. https://doi.org/10.1038/ja.2013.27.
207. Pokrovskaya, V, Baasov T. 2010. Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance. Expert Opin Drug Discov 5:883–902. https://doi.org/10.1517/17460441.2010.508069.
208. Sousa, J, Alves G, Fortuna A, Falcao A. 2014. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf 9:89–105. https://doi.org/10.2174/1574886308666140106154754.
209. Sharma, PC, Jain A, Jain S. 2009. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 66:587–604.
210. Zhanel, GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ. 2006. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med 5:437–465. https://doi.org/10.2165/00151829-200605060-00009.
211. Labischinski, H, Cherian J, Cleofe C, Boyce RS. February 2011. Hybrid antimicrobial compounds and their use. World Intellectual Property Organization patent WO2010025906.
212. Wang, X-D, Wei W, Wang P-F, Tang Y-T, Deng R-C, Li B, Zhou S-S, Zhang J-W, Zhang L, Xiao Z-P, Ouyang H, Zhu H-L. 2014. Novel 3-arylfuran- 2(5H)-one-fluoroquinolone hybrid: design, synthesis and evaluation as antibacterial agent. Bioorg Med Chem 22:3620–3628. https://doi.org/10.1016/j.bmc.2014.05.018.
213. Xiao, Z-P, Ma T-W, Liao M-L, Feng Y-T, Peng X-C, Li J-L, Li Z-P, Wu Y, Luo Q, Deng Y, Liang X, Zhu H-L. 2011. Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: synthesis, molecular docking and structure-activity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones. Eur J Med Chem 46:4904–4914. https://doi.org/10.1016/j.ejmech.2011.07.047.
214. Xiao, ZP, Wang XD, Wang PF, Zhou Y, Zhang JW, Zhang L, Zhou J, Zhou SS, Hui O, Lin XY, Mustapa M, Reyinbaike A, Zhu HL. 2014. Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. Eur J Med Chem 80:92–100. https://doi.org/10.1016/j.ejmech.2014.04.037.
215. Cushnie, TPT, Lamb AJ. 2005. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26:343–356. https://doi.org/10.1016/j.ijantimicag.2005.09.002.
216. Dzoyem, JP, Hamamoto H, Ngameni B, Ngadjui BT, Sekimizu K. 2013. Antimicrobial action mechanism of flavonoids from Dorstenia species. Drug Discov Ther 7:66–72.
217. Céliz, G, Daz M, Audisio MC. 2011. Antibacterial activity of naringin derivatives against pathogenic strains. J Appl Microbiol 111:731–738. https://doi.org/10.1111/j.1365-2672.2011.05070.x.
218. Zhang, FY, Du GJ, Zhang L, Zhang CL, Lu WL, Liang W. 2009. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res 26:914–925. https://doi.org/10.1007/s11095-008-9793-y.
219. Pokrovskaya, V, Belakhov V, Hainrichson M, Yaron S, Baasov T. 2009. Design, synthesis, and evaluation of novel fluoroquinoloneaminoglycoside hybrid antibiotics. J Med Chem 52:2243–2254. https://doi.org/10.1021/jm900028n.
220. Baasov, T, Pokrovskaya V, Belakhov V, Hainrichson M. October 2010. Conjugated antimicrobial agents. World Intellectual Property Organization patent WO2010113151.
221. Wang, KK, Stone LK, Lieberman TD, Shavit M, Baasov T, Kishony R. 2015. A hybrid drug limits resistance by evading the action of the multiple antibiotic resistance pathway. Mol Biol Evol 33:492–500. https://doi.org/10.1093/molbev/msv243.
222. Zhang, L, Chang J-J, Zhang S-L, Damu GLV, Geng R-X, Zhou C-H. 2013. Synthesis and bioactive evaluation of novel hybrids of metronidazole and berberine as new type of antimicrobial agents and their transportation behavior by human serum albumin. Bioorg Med Chem 21: 4158–4169. https://doi.org/10.1016/j.bmc.2013.05.007.
223. Jeyakkumar, P, Zhang L, Avula SR, Zhou C-H. 2016. Design, synthesis and biological evaluation of berberine-benzimidazole hybrids as new type of potentially DNA-targeting antimicrobial agents. Eur J Med Chem 122:205–215. https://doi.org/10.1016/j.ejmech.2016.06.031.
224. Dhondikubeer, R, Bera S, Zhanel GG, Schweizer F. 2012. Antibacterial activity of amphiphilic tobramycin. J Antibiot (Tokyo) 65:495–498. https://doi.org/10.1038/ja.2012.59.
225. Cochrane, SA, Li X, He S, Yu M, Wu M, Vederas JC. 2015. Synthesis of tridecaptin-antibiotic conjugates with in vivo activity against Gramnegative bacteria. J Med Chem 58:9779–9785. https://doi.org/10.1021/acs.jmedchem.5b01578.
226. Cochrane, SA, Vederas JC. 2014. Unacylated tridecaptin A(1) acts as an effective sensitiser of Gram-negative bacteria to other antibiotics. Int J Antimicrob Agents 44:493–499. https://doi.org/10.1016/j.ijantimicag.2014.08.008.
227. Cochrane, SA, Lohans CT, Brandelli JR, Mulvey G, Armstrong GD, Vederas JC. 2014. Synthesis and structure-activity relationship studies of N-terminal analogues of the antimicrobial peptide tridecaptin A(1). J Med Chem 57:1127–1131. https://doi.org/10.1021/jm401779d.
228. Schalk, IJ, Mislin GLA, Brillet K. 2012. Structure, function and binding selectivity and stereoselectivity of siderophore-iron outer membrane transporters. Curr Top Membr 69:37–66. https://doi.org/10.1016/B978-0-12-394390-3.00002-1.
229. Moynie, L, Luscher A, Rolo D, Pletzer D, Tortajada A, Weingart H, Braun Y, Page MGP, Naismith JH, Kohler T. 2017. Structure and function of the PiuA and PirA siderophore-drug receptors from Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 61:e02531-16. https://doi.org/10.1128/AAC.02531-16.
230. Miethke, M, Marahiel MA. 2007. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 71:413–451. https://doi.org/10.1128/MMBR.00012-07.
231. Wandersman, C, Delepelaire P. 2004. Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol 58:611–647. https://doi.org/10.1146/annurev.micro.58.030603.123811.
232. Straubinger, M, Blenk H, Naber KG, Wagenlehner FME. 2016. Urinary concentrations and antibacterial activity of BAL30072, a novel siderophore monosulfactam, against uropathogens after intravenous administration in healthy subjects. Antimicrob Agents Chemother 60: 3309–3315. https://doi.org/10.1128/AAC.02425-15.
233. Kim, A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP. 2015. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob Agents Chemother 59:7743–7752. https://doi.org/10.1128/AAC.00831-15.
234. Tomaras, AP, Crandon JL, McPherson CJ, Nicolau DP. 2015. Potentiation of antibacterial activity of the MB-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob Agents Chemother 59:2439–2442. https://doi.org/10.1128/AAC.04172-14.
235. Flanagan, ME, Brickner SJ, Lall M, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O’Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD. 2011. Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. ACS Med Chem Lett 2:385–390. https://doi.org/10.1021/ml200012f.
236. Maejima, T, Inoue M, Mitsuhashi S. 1991. In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother 35: 104–110. https://doi.org/10.1128/AAC.35.1.104.
237. Kohira, N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734. https://doi.org/10.1128/AAC.01695-15.
238. Ito, A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:670–677. https://doi.org/10.1093/jac/dkv402.
239. Monogue, ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. 2017. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother 61:e01022-17. https://doi.org/10.1128/AAC.01022-17.
240. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384–4386. https://doi.org/10.1128/AAC.03098-15.
241. Ito, A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401.
242. Tsuji, M, Horiyama T, Toba S, Nakamura R, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: in vivo efficacy in murine infection model caused by multidrug-resistant Gram-negative bacteria, abstr P0253. Abstr 25th Eur Congr Clin Microbiol Infect Dis.
243. Katsube, T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. 2017. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584–591. https://doi.org/10.1002/jcph.841.
244. Katsube, T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. 2017. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 61: e01381-16. https://doi.org/10.1128/AAC.01381-16.
245. Klahn, P, Bronstrup M. 2017. Bifunctional antimicrobial conjugates and hybrid antimicrobials. Nat Prod Rep 34:832–885. https://doi.org/10.1039/C7NP00006E.
246. Parkes, AL, Yule IA. 2016. Hybrid antibiotics— clinical progress and novel designs. Expert Opin Drug Discov 11:665–680. https://doi.org/10.1080/17460441.2016.1187597.
247. Gorityala, BK, Guchhait G, Fernando DM, Deo S, McKenna SA, Zhanel GG, Kumar A, Schweizer F. 2016. Adjuvants based on hybrid antibiotics overcome resistance in Pseudomonas aeruginosa and enhance fluoroquinolone efficacy. Angew Chem Int Ed Engl 55:555–559. https://doi.org/10.1002/anie.201508330.
248. Gorityala, BK, Guchhait G, Goswami S, Fernando DM, Kumar A, Zhanel GG, Schweizer F. 2016. Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux. J Med Chem 59:8441–8455. https://doi.org/10.1021/acs.jmedchem.6b00867.
249. Yang, X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F. 2017. A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant Gramnegative bacteria. J Med Chem 60:3913–3932. https://doi.org/10.1021/acs.jmedchem.7b00156.
250. Lyu, Y, Yang X, Goswami S, Gorityala BK, Idowu T, Domalaon R, Zhanel GG, Shan A, Schweizer F. 2017. Amphiphilic tobramycin-lysine conjugates sensitize multidrug resistant Gram-negative bacteria to rifampicin and minocycline. J Med Chem 60:3684–3702. https://doi.org/10.1021/acs.jmedchem.6b01742.
251. Lyu, Y, Domalaon R, Yang X, Schweizer F. 4 December 2017. Amphiphilic lysine conjugated to tobramycin synergizes legacy antibiotics against wild-type and multidrug-resistant Pseudomonas aeruginosa. Biopolymers https://doi.org/10.1002/bip.23091.
252. Domalaon, R, Yang X, Lyu Y, Zhanel GG, Schweizer F. 2017. Polymyxin, B3-tobramycin hybrids with Pseudomonas aeruginosa-selective antibacterial activity and strong potentiation of rifampicin, minocycline, and vancomycin. ACS Infect Dis 3:941–954. https://doi.org/10.1021/acsinfecdis.7b00145.
253. Odds, FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. https://doi.org/10.1093/jac/dkg301.
254. Khan, SN, Khan AU. 2016. Breaking the spell: combating multidrug resistant “superbugs.” Front Microbiol 7:174. https://doi.org/10.3389/fmicb.2016.00174.
255. Adler, A, Friedman ND, Marchaim D. 2016. Multidrug-resistant Gramnegative bacilli: infection control implications. Infect Dis Clin North Am 30:967–997. https://doi.org/10.1016/j.idc.2016.08.001.
256. Feldman, MB, Terry DS, Altman RB, Blanchard SC. 2010. Aminoglycoside activity observed on single pre-translocation ribosome complexes. Nat Chem Biol 6:54–62. https://doi.org/10.1038/nchembio.274.
257. Cheer, SM, Waugh J, Noble S. 2003. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 63:2501–2520. https://doi.org/10.2165/00003495-200363220-00015.
258. Tsai, CJ-Y, Loh JMS, Proft T. 2016. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence 7:214–229. https://doi.org/10.1080/21505594.2015.1135289.
259. Domalaon, R, Yang X, O’Neil J, Zhanel GG, Mookherjee N, Schweizer F. 2014. Structure-activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. Amino Acids 46:2517–2530. https://doi.org/10.1007/s00726-014-1806-z.
260. Brown, D. 2015. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov 14:821–832. https://doi.org/10.1038/nrd4675.
261. Idowu, T, Samadder P, Arthur G, Schweizer F. 2017. Amphiphilic modulation of glycosylated antitumor ether lipids results in a potent triamino scaffold against epithelial cancer cell lines and BT474 cancer stem cells. J Med Chem 60:9724–9738. https://doi.org/10.1021/acs.jmedchem.7b01198.
262. Idowu, T, Schweizer F. 2017. Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics (Basel) 6:E26. https://doi.org/10.3390/antibiotics6040026.
263. Guchhait, G, Altieri A, Gorityala B, Yang X, Findlay B, Zhanel GG, Mookherjee N, Schweizer F. 2015. Amphiphilic tobramycins with immunomodulatory properties. Angew Chem Int Ed Engl 54:6278–6282. https://doi.org/10.1002/anie.201500598.
264. Turner, MD, Nedjai B, Hurst T, Pennington DJ. 2014. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 1843:2563–2582. https://doi.org/10.1016/j.bbamcr.2014.05.014.
265. Nau, R, Eiffert H. 2002. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15:95–110. https://doi.org/10.1128/CMR.15.1.95-110.2002.
266. Freeman, BD, Natanson C. 2000. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Invest Drugs 9:1651–1663. https://doi.org/10.1517/13543784.9.7.1651.
267. Gziut, M, MacGregor HJ, Nevell TG, Mason T, Laight D, Shute JK. 2013. Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity. Br J Pharmacol 168: 1165–1181. https://doi.org/10.1111/bph.12018.
268. Choi, K-YG, Napper S, Mookherjee N. 2014. Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation. Immunology 143:68–80. https://doi.org/10.1111/imm.12291.
269. Bowdish, DME, Davidson DJ, Scott MG, Hancock REW. 2005. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49:1727–1732. https://doi.org/10.1128/AAC.49.5.1727-1732.2005.
270. Choi, K-Y, Chow LNY, Mookherjee N. 2012. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. J Innate Immun 4:361–370. https://doi.org/10.1159/000336630.
271. Scott, MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. 2002. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883–3891. https://doi.org/10.4049/jimmunol.169.7.3883.
272. Peterson, LR. 2001. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis 33(Suppl 3):S180–S186. https://doi.org/10.1086/321846.
273. Paul, K, Erhardt M, Hirano T, Blair DF, Hughes KT. 2008. Energy source of flagellar type III secretion. Nature 451:489–492. https://doi.org/10.1038/nature06497.
274. Feng, X, Zhu W, Schurig-Briccio LA, Lindert S, Shoen C, Hitchings R, Li J, Wang Y, Baig N, Zhou T, Kim BK, Crick DC, Cynamon M, McCammon JA, Gennis RB, Oldfield E. 2015. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci U S A 112:E7073–E7082. https://doi.org/10.1073/pnas.1521988112.
275. Pages, J-M, Masi M, Barbe J. 2005. Inhibitors of efflux pumps in Gramnegative bacteria. Trends Mol Med 11:382–389. https://doi.org/10.1016/j.molmed.2005.06.006.
276. Ejim, L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, Tyers M, Brown ED, Wright GD. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 7:348–350. https://doi.org/10.1038/nchembio.559.
277. Ghosh, C, Manjunath GB, Akkapeddi P, Yarlagadda V, Hoque J, Uppu DSSM, Konai MM, Haldar J. 2014. Small molecular antibacterial peptoid mimics: the simpler the better! J Med Chem 57:1428–1436. https://doi.org/10.1021/jm401680a.
278. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100S, 26th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
279. Kumar, A, Schweizer HP. 2005. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57:1486–1513. https://doi.org/10.1016/j.addr.2005.04.004.
280. Lau, CH-F, Hughes D, Poole K. 2014. MexY-promoted aminoglycoside resistance in Pseudomonas aeruginosa: involvement of a putative proximal binding pocket in aminoglycoside recognition. mBio 5:e01068-14. https://doi.org/10.1128/mBio.01068-14.
281. Sobel, ML, McKay GA, Poole K. 2003. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 47: 3202–3207. https://doi.org/10.1128/AAC.47.10.3202-3207.2003.
282. Brown, DG, May-Dracka TL, Gagnon MM, Tommasi R. 2014. Trends and exceptions of physical properties on antibacterial activity for Grampositive and Gram-negative pathogens. J Med Chem 57:10144–10161. https://doi.org/10.1021/jm501552x.
283. Kumar, A, Chua K-L, Schweizer HP. 2006. Method for regulated expression of single-copy efflux pump genes in a surrogate Pseudomonas aeruginosa strain: identification of the BpeEF-OprC chloramphenicol and trimethoprim efflux pump of Burkholderia pseudomallei 1026b. Antimicrob Agents Chemother 50:3460–3463. https://doi.org/10.1128/AAC.00440-06.
284. Lomovskaya, O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45:105–116. https://doi.org/10.1128/AAC.45.1.105-116.2001.
285. Matsushita, K, Inoue T, Adachi O, Toyama H. 2005. Acetobacter aceti possesses a proton motive force-dependent efflux system for acetic acid. J Bacteriol 187:4346–4352. https://doi.org/10.1128/JB.187.13.4346-4352.2005.
286. Schumacher, A, Steinke P, Bohnert JA, Akova M, Jonas D, Kern WV. 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother 57:344–348. https://doi.org/10.1093/jac/dki446.
287. Pannek, S, Higgins PG, Steinke P, Jonas D, Akova M, Bohnert JA, Seifert H, Kern WV. 2006. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J Antimicrob Chemother 57: 970–974. https://doi.org/10.1093/jac/dkl081.
288. Kern, WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 57:339–343. https://doi.org/10.1093/jac/dki445.
289. Bohnert, JA, Kern WV. 2005. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 49:849–852. https://doi.org/10.1128/AAC.49.2.849-852.2005.
290. Herzog, IM, Green KD, Berkov-Zrihen Y, Feldman M, Vidavski RR, Eldar- Boock A, Satchi-Fainaro R, Eldar A, Garneau-Tsodikova S, Fridman M. 2012. 6”-Thioether tobramycin analogues: towards selective targeting of bacterial membranes. Angew Chem Int Ed Engl 51:5652–5656. https://doi.org/10.1002/anie.201200761.
291. Van Bambeke F, Pages J-M, Lee VJ. 2006. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov 1:157–175. https://doi.org/10.2174/157489106777452692.
292. Kriengkauykiat, J, Porter E, Lomovskaya O, Wong-Beringer A. 2005. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49: 565–570. https://doi.org/10.1128/AAC.49.2.565-570.2005.
293. Vila, J, Martinez JL. 2008. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors. Curr Drug Targets 9:797–807. https://doi.org/10.2174/138945008785747806.
294. Idowu, T, Samadder P, Arthur G, Schweizer F. 2016. Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)- chlorambucil-hybrids. Chem Phys Lipids 194:139–148. https://doi.org/10.1016/j.chemphyslip.2015.07.003.
295. Ogunsina, M, Samadder P, Idowu T, Arthur G, Schweizer F. 2017. Replacing, D-glucosamine with its L-enantiomer in glycosylated antitumor ether lipids (GAELs) retains cytotoxic effects against epithelial cancer cells and cancer stem cells. J Med Chem 60:2142–2147. https://doi.org/10.1021/acs.jmedchem.6b01773.
296. Ling, LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schaberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K. 2015. A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459. https://doi.org/10.1038/nature14098.
297. Mitchell, P. 2011. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. 1966. Biochim, Biophys Acta 1807:1507–1538. https://doi.org/10.1016/j.bbabio.2011.09.018.
298. Kaneti, G, Meir O, Mor A. 2016. Controlling bacterial infections by inhibiting proton-dependent processes. Biochim Biophys Acta 1858: 995–1003. https://doi.org/10.1016/j.bbamem.2015.10.022.
299. Hancock, REW, Chapple DS. 1999. Peptide antibiotics. Antimicrob Agents Chemother 43:1317–1323.
300. Epand, RM, Vogel HJ. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11–28. https://doi.org/10.1016/S0005-2736(99)00198-4.
301. Epand, RF, Maloy WL, Ramamoorthy A, Epand RM. 2010. Probing the “charge cluster mechanism” in amphipathic helical cationic antimicrobial peptides. Biochemistry 49:4076–4084. https://doi.org/10.1021/bi100378m.
302. Blondelle, SE, Houghten RA. 1991. Hemolytic and antimicrobial activities of the twenty-four individual omission analogues of melittin. Biochemistry 30:4671–4678. https://doi.org/10.1021/bi00233a006.
303. Radzishevsky, IS, Rotem S, Zaknoon F, Gaidukov L, Dagan A, Mor A. 2005. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. Antimicrob Agents Chemother 49:2412–2420. https://doi.org/10.1128/AAC.49.6.2412-2420.2005.
304. Rotem, S, Radzishevsky I, Mor A. 2006. Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin de- rivatives. Antimicrob Agents Chemother 50:2666–2672. https://doi.org/10.1128/AAC.00030-06.
305. Marynka, K, Rotem S, Portnaya I, Cogan U, Mor A. 2007. In vitro discriminative antipseudomonal properties resulting from acyl substitution of N-terminal sequence of dermaseptin s4 derivatives. Chem Biol 14:75–85. https://doi.org/10.1016/j.chembiol.2006.11.009.
306. Higgins, DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE, Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 49: 1127–1134. https://doi.org/10.1128/AAC.49.3.1127-1134.2005.
307. Guskey, MT, Tsuji BT. 2010. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30:80–94. https://doi.org/10.1592/phco.30.1.80.
308. Han, Q, Zhao Q, Fish S, Simonsen KB, Vourloumis D, Froelich JM, Wall D, Hermann T. 2005. Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed Engl 44:2694–2700. https://doi.org/10.1002/anie.200500028.
309. Kipnis, E, Sawa T, Wiener-Kronish J. 2006. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 36:78–91. https://doi.org/10.1016/j.medmal.2005.10.007.
310. Mangoni, ML, Shai Y. 2011. Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell Mol Life Sci 68:2267–2280. https://doi.org/10.1007/s00018-011-0718-2.
311. Schweizer, F. 2009. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 625:190–194. https://doi.org/10.1016/j.ejphar.2009.08.043.
312. Vaara, M. 1992. Agents that increase the permeability of the outer membrane. Microbiol Rev 56:395–411.
313. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43:727–737.
314. Davis, BD. 1987. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 51:341–350.
315. Sautrey, G, El Khoury M, Dos Santos AG, Zimmermann L, Deleu M, Lins L, Decout J-L, Mingeot-Leclercq M-P. 2016. Negatively charged lipids as a potential target for new amphiphilic aminoglycoside antibiotics: a biophysical study. J Biol Chem 291:13864–13874. https://doi.org/10.1074/jbc.M115.665364.
316. Berkov-Zrihen Y, Herzog IM, Feldman M, Sonn-Segev A, Roichman Y, Fridman M. 2013. Di-alkylated paromomycin derivatives: targeting the membranes of gram positive pathogens that cause skin infections. Bioorg Med Chem 21:3624–3631. https://doi.org/10.1016/j.bmc.2013.03.046.
317. Berkov-Zrihen Y, Herzog IM, Benhamou RI, Feldman M, Steinbuch KB, Shaul P, Lerer S, Eldar A, Fridman M. 2015. Tobramycin and nebramine as pseudo-oligosaccharide scaffolds for the development of antimicrobial cationic amphiphiles. Chemistry 21:4340–4349. https://doi.org/10.1002/chem.201406404.
318. Zimmermann, L, Das I, Desire J, Sautrey G, Barros RSV, El Khoury M, Mingeot-Leclercq M-P, Decout J-L. 2016. New broad-spectrum antibacterial amphiphilic aminoglycosides active against resistant bacteria: from neamine derivatives to smaller neosamine analogues. J Med Chem 59:9350–9369. https://doi.org/10.1021/acs.jmedchem.6b00818.
319. Sautrey, G, Zimmermann L, Deleu M, Delbar A, Souza Machado L, Jeannot K, Van Bambeke F, Buyck JM, Decout J-L, Mingeot-Leclercq M-P. 2014. New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides. Antimicrob Agents Chemother 58:4420–4430. https://doi.org/10.1128/AAC.02536-13.
320. Ouberai, M, El Garch F, Bussiere A, Riou M, Alsteens D, Lins L, Baussanne I, Dufrene YF, Brasseur R, Decout J-L, Mingeot-Leclercq M-P. 2011. The, Pseudomonas aeruginosa membranes: a target for a new amphiphilic aminoglycoside derivative? Biochim Biophys Acta 1808:1716–1727. https://doi.org/10.1016/j.bbamem.2011.01.014.
321. Bera, S, Zhanel GG, Schweizer F. 2010. Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. J Antimicrob Chemother 65:1224–1227. https://doi.org/10.1093/jac/dkq083.
322. Bera, S, Zhanel GG, Schweizer F. 2008. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent Gram-positive activity. J Med Chem 51:6160–6164. https://doi.org/10.1021/jm800345u.
323. Endres, BT, Basseres E, Alam MJ, Garey KW. 2017. Cadazolid for the treatment of Clostridium difficile. Expert Opin Invest Drugs 26:509–514. https://doi.org/10.1080/13543784.2017.1304538.
324. Locher, HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W. 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:892–900. https://doi.org/10.1128/AAC.01830-13.
325. Locher, HH, Caspers P, Bruyere T, Schroeder S, Pfaff P, Knezevic A, Keck W, Ritz D. 2014. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:901–908. https://doi.org/10.1128/AAC.01831-13.
326. Louie, T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA. 2015. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 59: 6266–6273. https://doi.org/10.1128/AAC.00504-15.
327. Baldoni, D, Gutierrez M, Timmer W, Dingemanse J. 2014. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother 69:706–714. https://doi.org/10.1093/jac/dkt401.
328. Robertson, GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. 2008. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother 52: 2313–2323. https://doi.org/10.1128/AAC.01649-07.
329. Robertson, GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. 2008. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother 52:2324–2334. https://doi.org/10.1128/AAC.01651-07.
330. Butler, MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64:413–425. https://doi.org/10.1038/ja.2011.44.